The Potential and Future Perspectives of CRISPR-Cas 13 Technology in Cancer Therapy Application

Yuhe Chen

doi:10.62051/hb5xat65

Authors

Yuhe Chen

DOI:

https://doi.org/10.62051/hb5xat65

Keywords:

Cancer therapy, CRISPR-Cas9, CRISPR-Cas12, CRISPR-Cas13.

Abstract

Cancer remains a significant global health challenge due to its genetic complexity and the diverse mutations, epigenetic modifications, and dysregulated signaling pathways involved. This complexity complicates effective treatment strategies. The CRISPR system, particularly CRISPR - Cas13, presents a promising therapeutic tool, offering precise RNA targeting with high accuracy and sensitivity. This paper examines the potential of Cas 13 in cancer therapy, focusing on four key areas: the mechanism of Cas13, Cas13 applications in cancer treatment, challenges and limitations. The results of the study showed that CRISPR-Cas13 can not only be used as a potential cancer diagnostic tool, but also regulate abnormal mRNA mutations and reduce cancer risk. By knocking down oncogenic lncRNA, CRISPR-Cas13 can inhibit the proliferation and migration of cancer cells. CRISPR-Cas13 has the potential to reduce cancer incidence and reduce cancer mortality through early diagnosis and intervention. In the future, technical optimization to address the off-target effects of Cas13 will be the key to its application in cancer treatment.

Downloads

Download data is not yet available.

References

[1] Wu X, Kriz AJ, Sharp PA. Target specificity of the CRISPR-Cas9 system. Quant Biol. 2014;2(2):59–70.

[2] Cancer Statistics. NCI, 2024-05-09. Available at: www.cancer.gov/about-cancer/understanding/statistics. Accessed 2024-10-06.

[3] Shmakov S, et al. Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems. Molecular Cell, 2015, 60: 385–397.

[4] Hillary VE, Ceasar SA. A Review on the Mechanism and Applications of CRISPR/Cas9/Cas12/Cas13/Cas14 Proteins Utilized for Genome Engineering. Molecular Biotechnology, 2023, 65(3): 311-325.

[5] Lotfi M, Rezaei N. CRISPR/Cas13: A potential therapeutic option of COVID-19. Biomedicine & Pharmacotherapy, 2020, 131: 110738.

[6] Curti L, Pereyra-Bonnet F, Gimenez C. An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12. 2020.

[7] Huang CH, Lee KC, Doudna JA. Applications of CRISPR-Cas enzymes in cancer therapeutics and detection. Trends in Cancer, 2018, 4: 499–512.

[8] Chen F, Zhang C, Xue J, Wang F, Li Z. Molecular mechanism for target RNA recognition and cleavage of Cas13h. Nucleic Acids Research, 2024, 52(12): 7279–7291.

[9] Gootenberg JS, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science, 2017, 356: 438–442.

[10] Park RJ, Wang T, Koundakjian DF, et al. A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors. Nature Genetics, 2017, 49: 193–203.

[11] Shah-Neville W. CRISPR-CAS13: How Does the Technology Compare to Its Famous Cas9 Cousin? Labiotech.Eu, 2024-06-27. Available at: www.labiotech.eu/in-depth/crispr-cas-13/?nab=0. Accessed 2024-10-06.

[12] Taghavipour M, Sadoughi F, Mirzaei H, et al. Apoptotic functions of microRNAs in pathogenesis, diagnosis, and treatment of endometriosis. Cell Bioscience, 2020, 10(1): 12–18.

[13] Bruch R, et al. CRISPR/Cas13a-powered electrochemical microfluidic biosensor for nucleic acid amplification-free miRNA diagnostics. Advanced Materials, 2019, 31: 1905311.

[14] Kang M, Tang B, Li J, et al. Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA. Molecular Cancer, 2020, 19(1): 143.

[15] Masamha CP, Wagner EJ. The contribution of alternative polyadenylation to the cancer phenotype. Carcinogenesis, 2018, 39: 2–10.

[16] Konermann S, et al. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell, 2018, 173: 665–676.

[17] Anderson KM, Poosala P, Lindley SR, Anderson DM. Targeted cleavage and polyadenylation of RNA by CRISPR-Cas13. bioRxiv, 2019.

[18] Sciarrillo R, et al. The role of alternative splicing in cancer: from oncogenesis to drug resistance. Drug Resistance Updates, 2020, 53: 100728.

[19] Palaz F, Kalkan AK, Can O, et al. CRISPR-Cas13 system as a promising and versatile tool for cancer diagnosis, therapy, and research. ACS Synthetic Biology, 2021, 10(6): 1245-1267.

[20] Zhang Z, et al. CRISPR-Cas13-Mediated Knockdown of lncRNA-GACAT3 Inhibited Cell Proliferation and Motility, and Induced Apoptosis by Increasing p21, Bax, and E-Cadherin Expression in Bladder Cancer. Frontiers in Molecular Biosciences, 2021, 7: 627774.

[21] Zhang XH, et al. Off-target effects in CRISPR/Cas9-mediated genome engineering. Molecular Therapy - Nucleic Acids, 2015, 4: e264.